$1.68
+0.03 (+1.82%)
Open$1.68
Previous Close$1.65
Day High$1.69
Day Low$1.63
52W High$3.82
52W Low$0.56
Volume—
Avg Volume904.0K
Market Cap83.96M
P/E Ratio—
EPS$-0.83
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+742.9% upside
Current
$1.68
$1.68
Target
$14.16
$14.16
$9.87
$14.16 avg
$18.59
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.94M | 3.25M | 19.24M |
| Net Income | -89,065,412 | -134,269,465 | -3,136,016 |
| Profit Margin | -4,594.3% | -4,364.5% | -16.3% |
| EBITDA | -86,495,826 | -137,639,924 | -4,591,050 |
| Free Cash Flow | — | — | -2,958,449 |
| Rev Growth | -40.3% | -40.3% | -5.9% |
| Debt/Equity | 0.91 | 0.91 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.89 | +0.06% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $351.43 | +1.27% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.16 | +0.09% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $475.20 | +1.45% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $623.43 | +0.87% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $294.06 | +2.04% | 64.3 | 37.13B |